2022 IDWeeK美国感染性疾病周——新冠肺炎前沿速递( 四 ) _健康小知识

文章图片
综上， 2022年的IDWeek大会为我们带来了新冠肺炎高危人群及新冠中和抗体等方面的最新研究进展，这将给临床专家带来更多思考与见解，为更好地保护高危人群，治疗新冠肺炎提供更多的科学的思路和方向。
参考文献
IDWeek大会官网：https://idweek.org/
1.http://www.nhc.gov.cn/xcs/yqtb/list_gzbd.shtml
2.288-PrognosticFactorsforIn-hospitalMortalityofPatientswithSevereCOVID-19HospitalizedintheUniversityMedicalCenter,Lithuania.
3.1086-COVID-19inacomprehensiveCancerCenter:2020-2022.
4.1089-Evaluationofbreakthroughinfectionsinsolidorgantransplantrecipients:theprospectiveCONTRASTcohort.
5.1939-COVID-19vaccineimmunogenicityamongCD19receptorT-cell(CAR-T)therapy.
6.LevinMJ,etal.NEnglJMed.2022Jun9;386(23):2188-2200.
7.MontgomeryH,etal.LancetRespirMed.2022Jun7;S2213-2600(22)00180-1
8.1160-Treatment-EmergentViralVariantsinthePhase3TACKLETrialInvestigatingEfficacyandSafetyofAZD7442(Tixagevimab/Cilgavimab)fortheTreatmentofMildtoModerateCOVID-19inAdults1066-Precisionphenotypingof“longCOVID”throughmachinelearning.
9.1110-AZD7442(Tixagevimab/Cilgavimab)DemonstratesPotentInVitroActivityAgainstSARS-CoV-2SpikeVariantsIdentifiedinCirculationandinProphylaxisClinicalStudies
10.1143-ProphylacticandTherapeuticActivityofAZD7442(Tixagevimab/Cilgavimab)inSARS-CoV-2HamsterChallengeModels
11.1918-ImpactoftheSARS-CoV-2–NeutralizingAntibodyCombinationAZD7442(Tixagevimab/Cilgavimab)ontheSeverityandProgressionofCOVID-19SymptomsinthePhase3TACKLETrial
12.1924-OutpatientTreatmentWiththeSARS-CoV-2–NeutralizingAntibodyCombinationAZD7442(Tixagevimab/Cilgavimab)forPreventingCOVID-19HospitalizationsinthePhase3TACKLETrial
13.1925-PrevalenceofSARS-CoV-2InfectioninImmunocompromisedPatientsFollowingReceiptofTixagevimab/Cilgavimab